The results of an in vitro trial suggested that Sirt1/FoxO1 may be one of the potential therapeutic targets for LPS‐induced oxidative stress injury in rat insulinoma cells (Mo et al., 2019). This evidence concerns the gene SIRT1 and pancreatic insulinoma.